Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos
Ano de defesa: | 2022 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | , , , |
Tipo de documento: | Tese |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Federal de Santa Maria
Centro de Ciências da Saúde |
Programa de Pós-Graduação: |
Programa de Pós-Graduação em Ciências Farmacêuticas
|
Departamento: |
Análises Clínicas e Toxicológicas
|
País: |
Brasil
|
Palavras-chave em Português: | |
Palavras-chave em Inglês: | |
Área do conhecimento CNPq: | |
Link de acesso: | http://repositorio.ufsm.br/handle/1/26601 |
Resumo: | A pathological condition with a high level of severity, caused by drug resistance, is one of the major public health problems worldwide and has worrying consequences. This scenario becomes more complex when we mention the infections caused by the pathogens ESKAPE - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. - (because they are microorganisms with high multiresistance and virulence). Thus, repositioning has been a trending topic in the literature and consists of finding new uses for drugs approved for clinical use. In this sense, the present study aimed, in the published articles, to present to the scientific community the current research on treatment alternatives for infections caused by ESKAPE pathogens and perspectives on the anti-infective activities of proton pump inhibitors (PPIs). In the manuscripts, the biological activities of the benzodiazepines clonazepam and diazepam and PPIs omeprazole and esomeprazole as candidate drugs for redirection were verified. Scientific database searches were carried out on treatment alternatives for ESKAPE pathogens and anti-infective activities of PPIs. In addition, the in vitro antibacterial activities of clonazepam, diazepam, omeprazole and esomeprazole against American Type Culture Collection (ATCC) standard bacterial strains and clinical isolates of ESKAPE pathogens were analyzed, determining the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), its interactions with the standard antibacterial ciprofloxacin by the checkerboard method and determination of the fractional inhibitory concentration index (FICI). For clonazepam and diazepam, the clinical impact of the use of these drugs in repositioning was analyzed, and for omeprazole and esomeprazole, the ability to cleave plasmid DNA was verified, and molecules capable of cleavage can act as antibacterials. In the treatment alternatives for infections caused by ESKAPE pathogens, drugs from the pharmacological classes of antineoplastic, anti-inflammatory, antidepressant and antialcoholic have been reported. In the study covering the anti-infective activities of PPIs, activities of these drugs against 17 infectious agents were described, some of them Pseudomonas aeruginosa, Mycobacterium tuberculosis, Enterococcus faecalis, Staphylococcus aureus, Candida albicans and SARS-CoV-2. In antibacterial activity assays, the combination of clonazepam and diazepam with ciprofloxacin was synergistic against 10 strains and five strains of ESKAPE pathogens (FICI<0.5), respectively. The combination of omeprazole and esomeprazole with ciprofloxacin was synergistic against two strains and three strains of ESKAPE pathogens (FICI<0.5), respectively. In the plasmid DNA cleavage assay, it was evidenced that omeprazole and esomeprazole were able to cleave plasmid DNA under defined conditions of pH, temperature and reaction times, being hydrolytic the main mechanism involved (omeprazole 37ºC pH 7.4 and pH 8.0; esomeprazole 37°C pH 7.4 and pH 8.0 - 50°C pH 8.0). We conclude that drug redirection is a promising approach against bacterial infections caused by bacteria with high multi-resistance to antibacterials. Furthermore, we encourage the development of more in vitro and in vivo studies involving the antibacterial activity of benzodiazepines and proton pump inhibitors, in order to be implemented as adjuvants in cases of serious infections caused by pathogens such as ESKAPE. |
id |
UFSM_3e177484e9f64a741c84d104e2fea131 |
---|---|
oai_identifier_str |
oai:repositorio.ufsm.br:1/26601 |
network_acronym_str |
UFSM |
network_name_str |
Biblioteca Digital de Teses e Dissertações do UFSM |
repository_id_str |
|
spelling |
2022-10-19T19:22:08Z2022-10-19T19:22:08Z2022-09-22http://repositorio.ufsm.br/handle/1/26601A pathological condition with a high level of severity, caused by drug resistance, is one of the major public health problems worldwide and has worrying consequences. This scenario becomes more complex when we mention the infections caused by the pathogens ESKAPE - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. - (because they are microorganisms with high multiresistance and virulence). Thus, repositioning has been a trending topic in the literature and consists of finding new uses for drugs approved for clinical use. In this sense, the present study aimed, in the published articles, to present to the scientific community the current research on treatment alternatives for infections caused by ESKAPE pathogens and perspectives on the anti-infective activities of proton pump inhibitors (PPIs). In the manuscripts, the biological activities of the benzodiazepines clonazepam and diazepam and PPIs omeprazole and esomeprazole as candidate drugs for redirection were verified. Scientific database searches were carried out on treatment alternatives for ESKAPE pathogens and anti-infective activities of PPIs. In addition, the in vitro antibacterial activities of clonazepam, diazepam, omeprazole and esomeprazole against American Type Culture Collection (ATCC) standard bacterial strains and clinical isolates of ESKAPE pathogens were analyzed, determining the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), its interactions with the standard antibacterial ciprofloxacin by the checkerboard method and determination of the fractional inhibitory concentration index (FICI). For clonazepam and diazepam, the clinical impact of the use of these drugs in repositioning was analyzed, and for omeprazole and esomeprazole, the ability to cleave plasmid DNA was verified, and molecules capable of cleavage can act as antibacterials. In the treatment alternatives for infections caused by ESKAPE pathogens, drugs from the pharmacological classes of antineoplastic, anti-inflammatory, antidepressant and antialcoholic have been reported. In the study covering the anti-infective activities of PPIs, activities of these drugs against 17 infectious agents were described, some of them Pseudomonas aeruginosa, Mycobacterium tuberculosis, Enterococcus faecalis, Staphylococcus aureus, Candida albicans and SARS-CoV-2. In antibacterial activity assays, the combination of clonazepam and diazepam with ciprofloxacin was synergistic against 10 strains and five strains of ESKAPE pathogens (FICI<0.5), respectively. The combination of omeprazole and esomeprazole with ciprofloxacin was synergistic against two strains and three strains of ESKAPE pathogens (FICI<0.5), respectively. In the plasmid DNA cleavage assay, it was evidenced that omeprazole and esomeprazole were able to cleave plasmid DNA under defined conditions of pH, temperature and reaction times, being hydrolytic the main mechanism involved (omeprazole 37ºC pH 7.4 and pH 8.0; esomeprazole 37°C pH 7.4 and pH 8.0 - 50°C pH 8.0). We conclude that drug redirection is a promising approach against bacterial infections caused by bacteria with high multi-resistance to antibacterials. Furthermore, we encourage the development of more in vitro and in vivo studies involving the antibacterial activity of benzodiazepines and proton pump inhibitors, in order to be implemented as adjuvants in cases of serious infections caused by pathogens such as ESKAPE.Uma condição patológica com nível de gravidade alto, causado pela resistência a medicamentos, é um dos grandes problemas de saúde pública a nível mundial e apresenta consequências preocupantes. Esse cenário fica mais complexo quando citamos as infecções causadas pelos patógenos ESKAPE - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa e Enterobacter spp. - (por serem microrganismos com alta multirresistência e virulência). Com isso, o reposicionamento tem sido um tópico de tendência na literatura e consiste em encontrar novos usos para medicamentos aprovados para utilização na clínica. Nesse sentido, o presente estudo objetivou, nos artigos publicados, apresentar à comunidade científica a pesquisa atual sobre as alternativas de tratamento para infecções causadas por patógenos ESKAPE e perspectivas sobre as atividades anti-infecciosas dos inibidores da bomba de prótons (IBPs). Nos manuscritos, foram verificadas as atividades biológicas dos benzodiazepínicos clonazepam e diazepam e IBPs omeprazol e esomeprazol como medicamentos candidatos ao redirecionamento. Foram realizadas pesquisas em bases de dados científicas sobre alternativas de tratamento para patógenos ESKAPE e atividades anti-infecciosas de IBPs. Além disso, foram analisadas as atividades antibacterianas in vitro de clonazepam, diazepam, omeprazol e esomeprazol frente a cepas bacterianas padrão American Type Culture Collection (ATCC) e isolados clínicos de patógenos ESKAPE, determinando a concentração inibitória mínima (CIM), concentração bactericida mínima (CBM), suas interações com o antibacteriano padrão ciprofloxacino pelo método checkerboard e determinação do índice de concentração inibitória fracionada (FICI). Para clonazepam e diazepam foi analisado, adicionalmente, o impacto clínico do uso desses medicamentos no reposicionamento e para omeprazol e esomeprazol foi verificada a capacidade de clivagem do DNA plasmidial, sendo que moléculas com capacidade de clivagem podem atuar como antibacterianos. Nas alternativas de tratamento para infecções ocasionadas por patógenos ESKAPE, medicamentos das classes farmacológicas dos antineoplásicos, anti-inflamatórios, antidepressivos e antialcoólicos foram relatados. Já no estudo abrangendo as atividades anti-infecciosas dos IBPs, foram descritas atividades desses medicamentos frente a 17 agentes infecciosos, sendo alguns deles Pseudomonas aeruginosa, Mycobacterium tuberculosis, Enterococcus faecalis, Staphylococcus aureus, Candida albicans e SARS-CoV-2. Nos ensaios de atividade antibacteriana, a combinação de clonazepam e diazepam com ciprofloxacino foi sinérgica frente a 10 cepas e cinco cepas de patógenos ESKAPE (FICI<0,5), respectivamente. A combinação de omeprazol e esomeprazol com ciprofloxacino foi sinérgica frente a duas cepas e três cepas de patógenos ESKAPE (FICI<0,5), respectivamente. No ensaio de clivagem do DNA plasmidial foi evidenciado que omeprazol e esomeprazol foram aptos a clivar o DNA plasmidial em condições definidas de pH, temperatura e tempos de reação, sendo hidrolítico o principal mecanismo envolvido (omeprazol 37ºC pH 7,4 e pH 8,0; esomeprazol 37ºC pH 7,4 e pH 8,0 - 50º C pH 8,0). Concluímos que o redirecionamento de medicamentos é uma abordagem promissora frente a infecções bacterianas ocasionadas por bactérias com alta multirresistência a antibacterianos. Ainda, incentivamos o desenvolvimento de mais estudos in vitro e in vivo envolvendo a atividade antibacteriana de benzodiazepínicos e inibidores da bomba de prótons, a fim de poderem ser implementados como adjuvantes nos casos de infecções graves causadas por patógenos como os ESKAPE.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESporUniversidade Federal de Santa MariaCentro de Ciências da SaúdePrograma de Pós-Graduação em Ciências FarmacêuticasUFSMBrasilAnálises Clínicas e ToxicológicasAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessReposicionamento de medicamentosDoenças infecciosasBactériasClivagem do DNAInibidores da bomba de prótonsBenzodiazepínicosDrug repositioningInfectious diseasesBacteriaDNA cleavageProton pump inhibitorsBenzodiazepinesCNPQ::CIENCIAS DA SAUDE::FARMACIAReposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicosDrug repositioning in infectious diseases and evaluation of the biological activity of proton pump inhibitors and benzodiazepinesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisHorner, Rosmarihttp://lattes.cnpq.br/5907084134183708Santos, Aline Joana Rolina Wohlmuth Alves dosMotta, Amanda de Souza daRamos, Daniela FernandesLibrelotto, Daniele Rubert Nogueirahttp://lattes.cnpq.br/7337351861020844Rosa, Taciéli Fagundes da4003000000056006006006006006006005fdaffc5-abc5-4607-8952-fc5c4760b004ea8118aa-3a04-455e-9224-8419a5cf1721ce578765-c3ea-444f-a5c5-1bbe76c916501dba0cf9-dc5d-47a3-904e-9058afe1b5110323bbab-0eb4-4282-bc76-e17f6d6409307ed49f29-0f8c-4495-8b1b-7cb84d4d7aecreponame:Biblioteca Digital de Teses e Dissertações do UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805http://repositorio.ufsm.br/bitstream/1/26601/2/license_rdf4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81956http://repositorio.ufsm.br/bitstream/1/26601/3/license.txt2f0571ecee68693bd5cd3f17c1e075dfMD53ORIGINALTES_PPGCF_2022_ROSA_TACIÉLI.pdfTES_PPGCF_2022_ROSA_TACIÉLI.pdfTese de Doutoradoapplication/pdf2258235http://repositorio.ufsm.br/bitstream/1/26601/1/TES_PPGCF_2022_ROSA_TACI%c3%89LI.pdffc03ea633960ca7bd63bf369984fb87eMD511/266012022-10-19 16:22:08.189oai:repositorio.ufsm.br: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 Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2022-10-19T19:22:08Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM)false |
dc.title.por.fl_str_mv |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos |
dc.title.alternative.eng.fl_str_mv |
Drug repositioning in infectious diseases and evaluation of the biological activity of proton pump inhibitors and benzodiazepines |
title |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos |
spellingShingle |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos Rosa, Taciéli Fagundes da Reposicionamento de medicamentos Doenças infecciosas Bactérias Clivagem do DNA Inibidores da bomba de prótons Benzodiazepínicos Drug repositioning Infectious diseases Bacteria DNA cleavage Proton pump inhibitors Benzodiazepines CNPQ::CIENCIAS DA SAUDE::FARMACIA |
title_short |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos |
title_full |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos |
title_fullStr |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos |
title_full_unstemmed |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos |
title_sort |
Reposicionamento de medicamentos em doenças infecciosas e avaliação da atividade biológica de inibidores da bomba de prótons e benzodiazepínicos |
author |
Rosa, Taciéli Fagundes da |
author_facet |
Rosa, Taciéli Fagundes da |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Horner, Rosmari |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/5907084134183708 |
dc.contributor.referee1.fl_str_mv |
Santos, Aline Joana Rolina Wohlmuth Alves dos |
dc.contributor.referee2.fl_str_mv |
Motta, Amanda de Souza da |
dc.contributor.referee3.fl_str_mv |
Ramos, Daniela Fernandes |
dc.contributor.referee4.fl_str_mv |
Librelotto, Daniele Rubert Nogueira |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/7337351861020844 |
dc.contributor.author.fl_str_mv |
Rosa, Taciéli Fagundes da |
contributor_str_mv |
Horner, Rosmari Santos, Aline Joana Rolina Wohlmuth Alves dos Motta, Amanda de Souza da Ramos, Daniela Fernandes Librelotto, Daniele Rubert Nogueira |
dc.subject.por.fl_str_mv |
Reposicionamento de medicamentos Doenças infecciosas Bactérias Clivagem do DNA Inibidores da bomba de prótons Benzodiazepínicos |
topic |
Reposicionamento de medicamentos Doenças infecciosas Bactérias Clivagem do DNA Inibidores da bomba de prótons Benzodiazepínicos Drug repositioning Infectious diseases Bacteria DNA cleavage Proton pump inhibitors Benzodiazepines CNPQ::CIENCIAS DA SAUDE::FARMACIA |
dc.subject.eng.fl_str_mv |
Drug repositioning Infectious diseases Bacteria DNA cleavage Proton pump inhibitors Benzodiazepines |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE::FARMACIA |
description |
A pathological condition with a high level of severity, caused by drug resistance, is one of the major public health problems worldwide and has worrying consequences. This scenario becomes more complex when we mention the infections caused by the pathogens ESKAPE - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. - (because they are microorganisms with high multiresistance and virulence). Thus, repositioning has been a trending topic in the literature and consists of finding new uses for drugs approved for clinical use. In this sense, the present study aimed, in the published articles, to present to the scientific community the current research on treatment alternatives for infections caused by ESKAPE pathogens and perspectives on the anti-infective activities of proton pump inhibitors (PPIs). In the manuscripts, the biological activities of the benzodiazepines clonazepam and diazepam and PPIs omeprazole and esomeprazole as candidate drugs for redirection were verified. Scientific database searches were carried out on treatment alternatives for ESKAPE pathogens and anti-infective activities of PPIs. In addition, the in vitro antibacterial activities of clonazepam, diazepam, omeprazole and esomeprazole against American Type Culture Collection (ATCC) standard bacterial strains and clinical isolates of ESKAPE pathogens were analyzed, determining the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), its interactions with the standard antibacterial ciprofloxacin by the checkerboard method and determination of the fractional inhibitory concentration index (FICI). For clonazepam and diazepam, the clinical impact of the use of these drugs in repositioning was analyzed, and for omeprazole and esomeprazole, the ability to cleave plasmid DNA was verified, and molecules capable of cleavage can act as antibacterials. In the treatment alternatives for infections caused by ESKAPE pathogens, drugs from the pharmacological classes of antineoplastic, anti-inflammatory, antidepressant and antialcoholic have been reported. In the study covering the anti-infective activities of PPIs, activities of these drugs against 17 infectious agents were described, some of them Pseudomonas aeruginosa, Mycobacterium tuberculosis, Enterococcus faecalis, Staphylococcus aureus, Candida albicans and SARS-CoV-2. In antibacterial activity assays, the combination of clonazepam and diazepam with ciprofloxacin was synergistic against 10 strains and five strains of ESKAPE pathogens (FICI<0.5), respectively. The combination of omeprazole and esomeprazole with ciprofloxacin was synergistic against two strains and three strains of ESKAPE pathogens (FICI<0.5), respectively. In the plasmid DNA cleavage assay, it was evidenced that omeprazole and esomeprazole were able to cleave plasmid DNA under defined conditions of pH, temperature and reaction times, being hydrolytic the main mechanism involved (omeprazole 37ºC pH 7.4 and pH 8.0; esomeprazole 37°C pH 7.4 and pH 8.0 - 50°C pH 8.0). We conclude that drug redirection is a promising approach against bacterial infections caused by bacteria with high multi-resistance to antibacterials. Furthermore, we encourage the development of more in vitro and in vivo studies involving the antibacterial activity of benzodiazepines and proton pump inhibitors, in order to be implemented as adjuvants in cases of serious infections caused by pathogens such as ESKAPE. |
publishDate |
2022 |
dc.date.accessioned.fl_str_mv |
2022-10-19T19:22:08Z |
dc.date.available.fl_str_mv |
2022-10-19T19:22:08Z |
dc.date.issued.fl_str_mv |
2022-09-22 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/26601 |
url |
http://repositorio.ufsm.br/handle/1/26601 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.cnpq.fl_str_mv |
400300000005 |
dc.relation.confidence.fl_str_mv |
600 600 600 600 600 600 600 |
dc.relation.authority.fl_str_mv |
5fdaffc5-abc5-4607-8952-fc5c4760b004 ea8118aa-3a04-455e-9224-8419a5cf1721 ce578765-c3ea-444f-a5c5-1bbe76c91650 1dba0cf9-dc5d-47a3-904e-9058afe1b511 0323bbab-0eb4-4282-bc76-e17f6d640930 7ed49f29-0f8c-4495-8b1b-7cb84d4d7aec |
dc.rights.driver.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Centro de Ciências da Saúde |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências Farmacêuticas |
dc.publisher.initials.fl_str_mv |
UFSM |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Análises Clínicas e Toxicológicas |
publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Centro de Ciências da Saúde |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações do UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
instname_str |
Universidade Federal de Santa Maria (UFSM) |
instacron_str |
UFSM |
institution |
UFSM |
reponame_str |
Biblioteca Digital de Teses e Dissertações do UFSM |
collection |
Biblioteca Digital de Teses e Dissertações do UFSM |
bitstream.url.fl_str_mv |
http://repositorio.ufsm.br/bitstream/1/26601/2/license_rdf http://repositorio.ufsm.br/bitstream/1/26601/3/license.txt http://repositorio.ufsm.br/bitstream/1/26601/1/TES_PPGCF_2022_ROSA_TACI%c3%89LI.pdf |
bitstream.checksum.fl_str_mv |
4460e5956bc1d1639be9ae6146a50347 2f0571ecee68693bd5cd3f17c1e075df fc03ea633960ca7bd63bf369984fb87e |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM) |
repository.mail.fl_str_mv |
atendimento.sib@ufsm.br||tedebc@gmail.com |
_version_ |
1801485483632492544 |